Kornimate/medical-research-clean huggingface dataset:
a study of characterizing cognitive decline and functional cardiac senescence in healthy korean volunteers

Conditions: Aging; Mild Cognitive Impairment; Angina Pectoris

Summary: * although aging process appears to be generally characterized, investigators have been paid much attention to the specific target molecules, which leads to discover the clinical markers of the senescence. the present study is to investigate the clinical and biological profile of cognitive decline and functional cardiac senescence in healthy middle aged and elderly korean volunteers. * this study was conducted as a cross-sectional, single-center, comparative clinical study. * each volunteer was given informed consent for checking cognition and cardiac function. blood and urine samples were collected to analyze genome, proteome, and metabolome to assess cognition and cardiac function of its muscle enzymes.

* the protocol of this study was developed as the first assessment of the three to four series of clinical research on senescence. * this design of the study is a non-interventional, single-center, single-visit design for investigating the cognitive decline and cardiac function including heart muscle enzyme activity, which have been considered one of the key points in aging process. * volunteers visit the study site during the screening period, informed consent for study participation and blood draw are given respectively, then, the eligibilities are met, participants visit the study site just once within two weeks. * the participants undergo the following five procedures for 2-3 hours; out-patient visit, 1. additional demographic interview including covariate factors (depression status, marital status 2. vital sign check 3. the questionnaire for cognitive function 4. blood draw for genomic, proteomic, and metabolomic analyses (10 milli liter), urine collection (20 milli liter) 5. electrocardiogram (ecg), then they are discharged. * their safety follow-up is monitored in a week (± 1 day) by a phone-call from the study associates. * to evaluate cognitive function, several cognitive batteries were used, 3mse (modified-mini mental state examination), adas-cog (alzheimer's disease assessment scale-cognitive subscale); for cognitive biomarkers, apolipoprotein e, type-3 metabotropic glutamate receptors. * to evaluate cardiac function including its enzyme activity: hrv (heart rate variability), crp (c-reactive protein); cardiac troponin t.

Eligibility criteria:
inclusion criteria: * healthy subjects \>= 45 and \<= 80 years of age * who understands the study procedures signs informed consent forms exclusion criteria: * who \> 150 mmhg in systolic or \< 95 mmhg in diastolic blood pressure * who \> 110 mg/dl in fast glucose level * smoking \> 20 cigarettes/day * alcohol \> 3 units/day (1 unit = pure alcohol 10 milli liter) * caffeine \> 5 cups of coffee or tea/day

Keywords: genotype-phenotype association aged middle aged mild cognitive impairment heart rate control biomarkers
comparison of the efficacy of different steroids in the treatment of abnormal scars (keloids, hypertrophic scars)

Conditions: Keloid; Hypertrophic Scar; Scars; Scarring

Summary: comparison of the efficacy of different steroids in the treatment of abnormal scars (keloids and hypertrophic scars)

on a yearly basis, millions develop different skin scarring. these scars are a public reminder of the traumatic incident, past or present disease or a surgery which caused them. scarring is a common consequence of wound healing process, and it is one of the most complex biological processes in human. this healing process is affected by numerous factors and thus can be disrupted, leading to pathological scarring. pathological scarring is common in people with genetic predisposition, those undergone complex and massive surgeries, burns or those wounded in unsanitary environments. apart from being aesthetically unpleasant, scars are associated with functional and psychosocial morbidities. despite clinical, pathologic and pathogenic differences between keloids and hypertrophic scars, treatments are similar. scars have a negative external impact causing social distress and impaired self-image, and as a consequence, low satisfaction rates following surgical and cosmetic procedures. the first line treatment is monthly intralesional corticosteroid injections with a response rate of 50-100% and recurrence of 50%. there are a few steroids available and used for abnormal scars treatment, including celestone chronodose (betamethasone acetate + betamethasone sodium phosphate), dexamethasone sodium phosphate, methylprednisolone acetate, methylprednisolone sodium succinate, methylprednisolone hemisuccinate, triamcinolone acetonide. steroids are different by their hydrophilic properties, potency and half-life, although the half-life of intralesional injections is not known. inspite of being widely used, there have never been a comparative study of the different steroid treatments.

Eligibility criteria:
inclusion criteria: * 20 participants with at least 4 keloids * 20 participants with a hypertrophic scar of at least 11 cm length exclusion criteria: * current or planned pregnancy * breastfeeding women * participants suffering from diabetes mellitus or coagulation disorders * infection at planned injection sites * systemic treatment of corticosteroids, 5-fluorouracil * known allergy to any of the following: betamethasone acetate + betamethasone sodium phosphate, triamcinolone acetonide, dexamethasone sodium phosphate, methylprednisolone acetate
assessment of a knee brace in patients with osteoarthritis

Conditions: Osteoarthritis

Summary: it is a controlled clinical trial randomized, double-blind evaluator. will be considered eligible patients, individuals of both sexes, aged 40 -60, to submit at least four items of knee osteoarthrosis classification criteria, according to the american college of rheumatology, pain above four points in the visual analogue scale (vas), diagnosed with knee osteoarthritis and who sought physical therapy treatment. patients will be randomized by a number sequence generated by a computer using microsoft excel (microsoft corporation, redmond, washington), in opaque envelopes by researcher who will not attend the study.patients will be divided into two groups: group with knee patellar hole or group without knee patellar hole. shortly after the selection of the knee, the patient will have his eyes blind or cover in order to keep it '' blind '' regarding the type of knee brace that it would use. finally evaluator 1 will cover the knee with a black cloak, making the second evaluator ''blind '' regarding the type of knee brace that will be used. two investigators will carry out the data collection. the first evaluator will collect information on the clinical characteristics of patients, including evaluation form, numerical pain scale, which measures the intensity of pain, test time up and go (tug) test that measures the basic mobility of movement and test walking eight meters, whose purpose is to measure the time that the individual takes to walk a distance of eight meters.


Eligibility criteria:
inclusion criteria: * individuals of both sexes * aged 40 -60 * at least four items of knee osteoarthrosis classification criteria, according to the american college of rheumatology, * pain above four points in the visual analogue scale (vas) * diagnosed with knee osteoarthritis * no physical therapy treatment prior exclusion criteria: * neurological impairment * partial or total knee prosthesis * cardio-respiratory diseases * pregnant women * individuals who failed to perform the tests proposed
combination of btk inhibitor overcomes drug-resistance in refractory/relapsed flt3 mutant aml

Conditions: FLT3-ITD Mutation; Acute Myeloid Leukemia; Brutons Tyrosine Kinase

Summary: clinical efficacy of flt3 inhibitors combining with chemotherapy is usually transient and followed by emergence of drug-resistance in flt3-itd mutant aml. btk is reported to be a therapeutic target in this subtype leukemia. our previous study showed inhibition of btk onvercome drug-resistance to flt3 inhibitors/chemotherapy in refractory/relapsed flt3 mutant aml. in this prospective randomized controlled study, the efficacy and safety of combination of btk inhibitor with chemotherapy with/without flt3 inhibitor in refractory/relapsed flt3 mutant aml are evaluated.

clinical efficacy of flt3 inhibitors combining with chemotherapy is usually transient and followed by emergence of drug-resistance in flt3-itd mutant acute myeloid leukemia (aml). how to overcome the resistance to flt3 inhibitors or chemotherapy needs further study. bruton's tyrosine kinase (btk) is reported to be a therapeutic target in this subtype leukemia. our previous study showed inhibition of btk onvercome drug-resistance to flt3 inhibitors/chemotherapy in refractory/relapsed flt3 mutant aml. in this prospective randomized controlled study, we are going to inhibit btk with btk inhibitor ibrutinib in the patients with refractory/relapsed flt3 mutant aml, and then test the enhancing effect and safety of combination of ibrutinib with chemotherapy with/without flt3 inhibitor, to make sure inhibition of btk overcomes drug-resistance in flt3 mutation aml.

Eligibility criteria:
inclusion criteria: refractoty/relapsed flt3-itd mutation aml age 14-60 exclusion criteria: any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) patients with any conditions not suitable for the trial (investigators' decision)
a safety and efficacy study of inc280 and gefitinib in patients with egfr mutated, c-met-amplified nsclc who have progressed after egfri treatment

Conditions: Non-small Cell Lung Cancer

Summary: this study assessed the safety and efficacy of escalating doses inc280 when added to gefitinib in patients with lung cancer that were known to have dysregulation of the c-met pathway and who had failed after benefiting on a prior treatment with either gefitinib or erlotinib.

the phase ib dose escalation part was aimed at the determination of the mtd/rp2d of capmatinib in combination with 250 mg gefitinib in patients with nsclc patients with epidermal growth factor receptor (egfr) mutation and cmet dysregulation and showing disease progression following egfr tyrosine-kinase inhibitor (egfr tki) therapy. dose escalation started with a dose of 100 mg/day to a maximum of 1200 mg/day, as capsule or tablet formulation. successive cohorts of patients were to receive increasing doses of capmatinib in combination with a 250 mg once daily (qd) dose of gefitinib until the mtd/rp2d of capmatinib had been determined. the phase ii dose expansion part consisted of 400 mg capmatinib twice daily (bid), as either capsules or tablets, in combination with 250 mg gefitinib.

Eligibility criteria:
inclusion criteria: * documented egfr mutation * documented c-met dysregulation * prior clinical benefit on egfr inhibitors and then subsequent progression -≥ 18 year old * life expectancy of ≥ 3 months * ecog performance status ≤ 2 exclusion criteria: * unable to swallow tables once or twice daily * previous treatment with c-met inhibitor * any unresolved toxicity from previous anticancer therapy greater than grade 1 * history of cystic fibrosis * history of acute or chronic pancreatitis * unable to undergo mri or ct scans * known history of hiv * undergone a bone marrow or solid organ transplant * clinically significant wound or lung tumor lesions with increased likelihood of bleeding * pregnant or nursing

Keywords: egfr c-met lung cancer gefitinib erlotinib non-small cell lung cancer (nsclc) lung adenocarcinoma large-cell lung carcinoma
question prompt list for common hand conditions

Conditions: Carpal Tunnel Syndrome; Trigger Finger; Trigger Thumb; Dupuytren Contracture; Ganglion Cysts

Summary: patients with common hand conditions will be randomized to one of two groups- one will receive a question prompt list, the other will receive a list of 3 questions


Eligibility criteria:
inclusion criteria: * patients with common hand conditions exclusion criteria: -
oligoantigenic diet and core symptomatology of children with attention-deficit /hyperactivity disorder (adhd).

Conditions: Attention Deficit Disorder

Summary: fifty patients who diagnosed as adhd syndrome according to diagnostic and statistical manual of mental disorders, 5th edition (dsm 5) criteria aged from 6 to 16 years old will be assigned randomly into 2 arms: arm 1: the patients will follow food regimen that cover recommended daily allowance (rda) for macronutrients and micronutrients suitable for their ages without any food restriction, arm 2: the patients will follow food regimen that cover (rda) for macronutrients and micronutrients suitable for their ages based on oligoantigenic diet (oad). psychiatric assessment will be done before intervention and after 3 months of intervention.


Eligibility criteria:
inclusion criteria: * children fulfilled dsm (5) criteria for adhd syndrome aged from 6 to 16 years old on stable pharmacotherapy 8 weeks prior to enrollment with intention to maintain ongoing therapies constant throughout the trial. exclusion criteria: * presence of other medical conditions as chronic medical illness or other neuropsychiatric disorders * intelligence quotient (iq) of patients less than 80%.
database for predicting clinical outcomes of critically ill patients

Conditions: Critical Illness

Summary: australian and new zealand intensive care society (anzics) has built a center of outcome and resource evaluation (core) adult patients database (apd) of adult critically ill patients. anzics core apd has built an international collaboration of icu database. national taiwan university hospital has joined this international collaboration and built the data according to the apd data dictionary with same value domain attributes and data element attributes. we retrospectively collected the data of patients discharged from the march 1, 2019 to june 30, 2022. data of this database are permitted to study clinical problems and predict the clinical outcomes of these critically ill patients using statistical methods and machine learning techniques.

data of this database are permitted to study the following clinical issues: including delirium, sepsis, acute kidney injury, acute respiratory distress syndrome, disseminated intravascular coagulation, multiple organ injuries, nutrition, survival status, number of days on ventilators, need for renal replacement therapy, length of stays in intensive care unit, length of stay in hospital, and other relevant clinical outcomes. it is also planned to analyze the clinical prognosis of special disease subgroups and establish a prediction model according to the type of patient's disease.

Eligibility criteria:
inclusion criteria: * critically ill patients admitted to intensive care units exclusion criteria: * patients aged less than 18 years
endoscopic lung volume reduction coil treatment in patients with chronic hypercapnic respiratory failure

Conditions: Emphysema

Summary: endoscopic lung volume reduction coil treatment is a treatment option for selected patients with severe emphysema. in the advanced stages, emphysema may lead to chronic hypercapnic respiratory failure. in this observational study the safety and efficacy of endoscopic lung volume reduction coil treatment in patients with chronic hypercapnic respiratory failure is evaluated.


Eligibility criteria:
inclusion criteria: * patients with emphysema (chronic obstructive pulmonary disease with forced expired volume in one second (fev1) \< 50% predicted and residual volume (rv) ≥ 200% predicted) in whom endoscopic lung volume reduction coil treatment is performed * chronic hypercapnic respiratory failure (paco2 ≥ 50 mmhg) * informed consent exclusion criteria: * therapeutic anticoagulation * anti-platelet therapy exceeding the use of acetylsalicylic acid * severe pulmonary hypertension
safety, tolerability and immunogenicity of the candidate vaccine mva-sars-2-st against covid-19

Conditions: Covid19

Summary: multi-center phase ib study to evaluate the modified vaccinia virus ankara (mva) vaccine against sars-cov-2 in seronegative (part a) and previously sars-cov-2-vaccinated individuals (part b).

the vaccine contains a modified vaccinia virus ankara (mva) vector expressing a stabilized sars-cov-2 spike protein (s). this will be a phase ib multi-center study in approximately 60 adults aged 18-64 years. part a (n=24 seronegative subjects). each participant will receive two single injections, 28 days apart. * low dose ≥ 1 x 10e7 iu (n=8) * middle dose ≥ 5 x 10e7 iu (n=8) * high dose ≥ 1 x 10e8 iu (n=8) part b (n=36 previously mrna vaccinated subjects). each participant will receive a single injection. * low dose ≥ 1 x 10e7 iu (n=12) * middle dose ≥ 5 x 10e7 iu (n=12) * high dose ≥ 1 x 10e8 iu (n=12) all participants will be followed up for safety until d168.

Eligibility criteria:
inclusion criteria: 1. written informed consent. 2. healthy male and female adults aged 18 - 64 at time of informed consent. 3. body mass index 18.5 - 32.0 kg/m2 and weight \> 50 kg at screening. 4. female participants: non-pregnant, non-lactating with negative pregnancy test. 5. females who agree to comply with the applicable contraceptive requirements of the protocol. 6. ≥ 6 months fully vaccinated with a (conditionally)licensed mrna vaccine against covid-19 (part b only) exclusion criteria: 1. receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live vaccines) to 6 weeks after each trial vaccination. 2. previous rmva immunization. 3. previous immunization with investigational vaccine against covid-19. 4. previous immunization with eua/conditionally licensed vaccine against covid-19 (not applicable to part b). 5. evidence of active sars-cov-2 infection 6. known allergy to the components of the mva-sars-2-st vaccine product or history of life-threatening reactions to vaccine containing the same substances. 7. known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccines. 8. evidence in the participant's medical history or in the medical examination that might influence either the safety of the participant or the absorption, distribution, metabolism or excretion of the investigational product. 9. clinically relevant findings in ecg or significant thromboembolic events in medical history. 10. any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or uncontrolled diabetes (hba1c ≥ 7.0). 11. any known chronic or active neurologic disorder, including seizures and epilepsy, excluding a single febrile seizure as a child.

Keywords: mva sars-cov-2 vaccine booster vaccination
effectiveness of manual therapy and neuromuscular training in the management of knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the purpose of the study is to compare the short-term effectiveness of manual therapy with neuromuscular training and conventional physical therapy with neuromuscular training in patients with knee osteoarthritis.

knee osteoarthritis (oa) is a major public health problem, characterized by progressive degeneration and loss of articular cartilage, resulting in pain, limitation of movement, imbalance, functional disability, and diminished patient quality of life. regular participation in physical activity has been recognized for several years as being beneficial in the management of knee oa. the role and effectiveness of manual therapy techniques and conventional physical therapy are evident from the existing literature, but no comparison was found for the combination of neuromuscular training (nmt) in patients with knee oa. thus, the aim of this study is to compare the short-term effectiveness of manual therapy (mt) versus conventional physical therapy (cpt) with nmt in the management of knee oa after six weeks of treatment.

Eligibility criteria:
inclusion criteria: * complaining of knee pain that has lasted longer than 3 months. * pain level that is medium (pain score greater than or equal to 4). * no knee injuries. * treatment not received in another physical therapy clinic in the past three months. * painful range of motion in the knee. exclusion criteria: * history of knee surgery * a systemic arthritic condition * any other muscular, joint, or neurological condition affecting lower limb function. * received physical therapy or an intra-articular injection in the knee within the past 3 months.

Keywords: knee osteoarthritis manual therapy tens neuromuscular training
evaluation of a novel endoscopic treatment for achalasia

Conditions: Achalasia

Summary: this study is to evaluate outcomes of a less invasive surgical procedure for the treatment of achalasia.

this study will assess the feasibility and efficacy of a novel endoscopic procedure, per-oral endoscopic esophagomyotomy (poem)in treating patients with achalasia.

Eligibility criteria:
inclusion criteria: * o subjects with a manometric/radiologic diagnosis of primary achalasia; egd shows no neoplasm * ability to undergo general anesthesia * the subject is \> 18 yrs.of age * ability to give informed consent exclusion criteria: * o sigmoid achalasia * contraindicated for egd * pregnancy

Keywords: dysphagia
study to evaluate safety and efficacy of wc3011 (estradiol vaginal cream) in postmenopausal women with dyspareunia

Conditions: Vulvovaginal Atrophy

Summary: the purpose of the study is to determine if wc3011 is safe and effective in treating the symptom of painful intercourse secondary to vulvovaginal atrophy as measured by participant self-assessment when compared to vehicle.


Eligibility criteria:
inclusion criteria: * sexually active with self-identified dyspareunia (pain with sexual activity), at least moderate to severe and most bothersome symptom of vulvovaginal atrophy (vva) * postmenopausal and meets 1 of the following: 12 months spontaneous amenorrhea, 6 months spontaneous amenorrhea with fsh (follicle stimulating hormone) \>40 miu/ml,6 weeks postsurgical bilateral oophorectomy with confirmation by fsh \>40 miu/ml, surgical report or ultrasound, 6 weeks postsurgical hysterectomy with ovary failure confirmed by fsh \>40 miu/ml * age ≥40 years; ≥35 with bilateral oophorectomy * vaginal ph \>5.0 * less than or equal to 5% superficial cells on vaginal wall cytologic smear * normal clinical breast exam or negative mammogram if ≥ 40 years of age * negative urine pregnancy test (non-hysterectomized and \<12 months amenorrhea) exclusion criteria: * enrollment in sponsor's study pr-04409 or pr-05812 * participation in clinical trial or use of investigational drug within 30 days prior to screening * known hypersensitivity to estrogen and/or progestin therapy * known or suspected premalignant or malignant disease or history steroid-dependent malignancy * manifestation or treatment for significant cardiovascular disease (congestive heart failure, stroke or ischemic attack, myocardial infarction, coronary artery bypass, percutaneous angioplasty or \>50% angiographic narrowing of coronary artery * thrombophlebitis or thromboembolic disorder or history of * insulin-dependent diabetes mellitus * increased frequency or severity of headaches while on hormone or estrogen therapy * currently taking st. john's wort * drug/alcohol addiction within past 2 years * treatment with anticoagulants (heparin or warfarin) * smoking ≥15 cigarettes/day

Keywords: vulvovaginal atrophy dyspareunia postmenopausal